Biochemical implication of acetylcholine, histamine, IL‐18, and interferon‐alpha as diagnostic biomarkers in hepatitis C virus, coronavirus disease 2019, and dual hepatitis C virus‐coronavirus disease 2019 patients

Author:

Sakr Amany Awad1ORCID,Mohamed Amal Ahmed2,Ahmed Amr E.1,Abdelhaleem Ahmed A.3,Samir Hussein H.4,Elkady Mohammad Abdelkhalik5,Hasona Nabil A.6

Affiliation:

1. Department of Biotechnology, Faculty of Postgraduate Studies for Advanced Sciences Beni‐Suef University Beni‐Suef Egypt

2. Biochemistry and Molecular Biology Department National Hepatology and Tropical Medicine Research Institute (NHTMRI) Cairo Egypt

3. Tropical Department National Hepatology and Tropical Medicine Research Institute (NHTMRI) Cairo Egypt

4. Nephrology Unit, Internal Medicine Department, School of Medicine Cairo University Giza Egypt

5. Gastroenterology Department Theodor Bilharz Research Institute Giza Egypt

6. Biochemistry Department, Faculty of Science Beni‐Suef University Beni‐Suef Egypt

Abstract

AbstractGlobally, hepatitis C virus (HCV) and coronavirus disease 2019 (COVID‐19) are the most common causes of death due to the lack of early predictive and diagnostic tools. Therefore, research for a new biomarker is crucial. Inflammatory biomarkers are critical central players in the pathogenesis of viral infections. IL‐18, produced by macrophages in early viral infections, triggers inflammatory biomarkers and interferon production, crucial for viral host defense. Finding out IL‐18 function can help understand COVID‐19 pathophysiology and predict disease prognosis. Histamine and its receptors regulate allergic lung responses, with H1 receptor inhibition potentially reducing inflammation in severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection. angiotensin‐converting enzyme 2 (ACE‐2) receptors on cholangiocytes suggest liver involvement in SARS‐CoV‐2 infection. The current study presents the potential impact of circulating acetylcholine, histamine, IL‐18, and interferon‐Alpha as diagnostic tools in HCV, COVID‐19, and dual HCV‐COVID‐19 pathogenesis. The current study was a prospective cross‐section conducted on 188 participants classified into the following four groups: Group 1 COVID‐19 (n = 47), Group 2 HCV (n = 47), and Group 3 HCV‐COVID‐19 patients (n = 47), besides the healthy control Group 4 (n = 47). The levels of acetylcholine, histamine, IL‐18, and interferon‐alpha were assayed using the ELISA method. Liver and kidney functions within all groups showed a marked alteration compared to the healthy control group. Our statistical analysis found that individuals with dual infection with HCV‐COVID‐19 had high ferritin levels compared to other biomarkers while those with COVID‐19 infection had high levels of D‐Dimer. The histamine, acetylcholine, and IL‐18 biomarkers in both COVID‐19 and dual HCV‐COVID‐19 groups have shown discriminatory power, making them potential diagnostic tests for infection. These three biomarkers showed satisfactory performance in identifying HCV infection. The IFN‐Alpha test performed well in the HCV‐COVID‐19 group and was fair in the COVID‐19 group, but it had little discriminative value in the HCV group. Moreover, our findings highlighted the pivotal role of acetylcholine, histamine, IL‐18, and interferon‐Alpha in HCV, COVID‐19, and dual HCV‐COVID‐19 infection. Circulating levels of acetylcholine, histamine, IL‐18, and interferon‐Alpha can be potential early indicators for HCV, COVID‐19, and dual HCV‐COVID‐19 infection. We acknowledge that further large multicenter experimental studies are needed to further investigate the role biomarkers play in influencing the likelihood of infection to confirm and extend our observations and to better understand and ultimately prevent or treat these diseases.

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3